Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00174369
Status:
TERMINATED
Last Update Posted:
2009-03-17
First Post:
2005-09-09
Brief Title:
MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 2 Study Of The MEK Inhibitor PD-0325901 In Patients With Advanced Non-Small Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated See Detailed Description for Termination Reason
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells PD-325901 is a new drug designed to block this pathway and kill cancer cells The purpose of this study is to study the effectiveness of PD-325901 in patients with non-small cell lung cancer PD-325901 will be given by mouth as a pill twice a day CT scans will be done and biopsies of a tumor and a blood sample will be taken before treatment to examine the how genes affect tumor response to the study medication Blood samples will be taken to measure the amount of drug in the blood
Detailed Description:
This study was terminated prematurely on 23 March 2007 due to safety issues ocular and neurological toxicity observed in another PD-0325901 study A4581001 as well as lack of objective responses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None